Boston Scientific Cuts Forecast on Product Slowdown and Competition
Boston Scientific Corporation (NYSE: BSX ) stock is trading lower after the company cut its fiscal 2026 outlook, citing pressures on the Watchman and EP markets. Q2 Beats Estimates The medical technology giant reported revenues of $5.442 billion on Wednesday, better than the consensus estimate of $5.361 billion, beatin